Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) had its price objective cut by analysts at Roth Mkm from $15.00 to $8.00 in a report released on Monday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock.
Separately, StockNews.com began coverage on shares of Aptevo Therapeutics in a research note on Thursday. They set a “sell” rating on the stock.
Get Our Latest Stock Report on Aptevo Therapeutics
Aptevo Therapeutics Stock Performance
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.93) by $0.26. As a group, analysts anticipate that Aptevo Therapeutics will post -4.3 EPS for the current year.
Institutional Investors Weigh In On Aptevo Therapeutics
A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 8.06% of the company’s stock.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Featured Articles
- Five stocks we like better than Aptevo Therapeutics
- Canada Bond Market Holiday: How to Invest and Trade
- FedEx Stock Slowdown Signals Potential Dip Opportunity
- The Role Economic Reports Play in a Successful Investment Strategy
- Jump on Intel Now: Qualcomm’s Bid Could Ignite a Rally
- Why is the Ex-Dividend Date Significant to Investors?
- 3 Beaten Up Experiential Stocks to Cash in on a Good Time
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.